Lundbeck in neurodegeneration collaboration with ImaginAb

ImaginAb Inc, a clinical-stage US company developing in vivo molecular imaging agents based on antibody fragment technology, has entered into a collaboration and commercialization agreement with Denmark’s Lundbeck (LUN: CO) around a novel central nervous system (CNS) target in order to explore the use of re-engineered antibodies to accelerate the blood-brain barrier (BBB) transport of biologics.

"This collaboration represents a great opportunity for both companies to explore an increasingly important intersection between therapeutic and diagnostic medicine," said Christian Behrenbruch, chief executive of ImaginAb, adding: "Given the worrying number of recent failures of late-stage biologics programs, including for neurodegenerative applications, there is a critical need to explore new ways of integrating diagnostic and therapeutic strategies to de-risk development."

Option for therapeutic and diagnostic applications